Pfizer is one of the world’s largest pharmaceutical companies, with a heritage spanning 175 years. The company gained unprecedented visibility through its COVID-19 vaccine (Comirnaty) and oral antiviral (Paxlovid), though revenue is normalizing post-pandemic.
Oncology, Vaccines, Internal Medicine, Rare Diseases
5-year financial trajectory
Business segment breakdown
Key product revenue comparison
Geographic revenue split
| Product | Indication | Revenue |
|---|---|---|
| Comirnaty (COVID vaccine) | Infectious Diseases | $11.2B |
| Paxlovid (COVID antiviral) | Infectious Diseases | $2.0B |
| Eliquis (apixaban) | Cardiology | $6.3B |
| Ibrance (palbociclib) | Oncology | $4.4B |
| Vyndaqel (tafamidis) | Cardiology | $3.3B |
| Prevnar (pneumococcal) | Vaccines | $6.4B |
Pfizer is the #1 pharma company by revenue. Post-COVID revenue normalization is the primary challenge. The Seagen acquisition ($43B) strengthens oncology pipeline with ADCs.
Revenue stabilizing at $55-60B as COVID franchise transitions to endemic. Seagen acquisition adds $3-5B in oncology revenue. mRNA platform expansion (flu, RSV) represents long-term growth.
Pfizer 2023 Annual Report (Form 10-K). Revenue and financial data from SEC filings (Form 10-K/20-F). Pipeline data from company R&D presentations and ClinicalTrials.gov. Market analysis by Medifirm Intelledge Global.